171 related articles for article (PubMed ID: 25556956)
41. Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression.
Lee J; Park SY; Lee EK; Park CG; Chung HC; Rha SY; Kim YK; Bae GU; Kim BK; Han JW; Lee HY
Clin Cancer Res; 2006 Nov; 12(21):6351-8. PubMed ID: 17085645
[TBL] [Abstract][Full Text] [Related]
42. Hypoxia regulates the expression and localization of CCAAT/enhancer binding protein α by hypoxia inducible factor-1α in bladder transitional carcinoma cells.
Xue M; Li X; Chen W
Mol Med Rep; 2015 Aug; 12(2):2121-7. PubMed ID: 25824695
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobody.
Kazemi-Lomedasht F; Behdani M; Bagheri KP; Habibi-Anbouhi M; Abolhassani M; Arezumand R; Shahbazzadeh D; Mirzahoseini H
Mol Immunol; 2015 May; 65(1):58-67. PubMed ID: 25645505
[TBL] [Abstract][Full Text] [Related]
44. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway.
Tan C; de Noronha RG; Roecker AJ; Pyrzynska B; Khwaja F; Zhang Z; Zhang H; Teng Q; Nicholson AC; Giannakakou P; Zhou W; Olson JJ; Pereira MM; Nicolaou KC; Van Meir EG
Cancer Res; 2005 Jan; 65(2):605-12. PubMed ID: 15695405
[TBL] [Abstract][Full Text] [Related]
45. HIF-1α suppressing small molecule, LW6, inhibits cancer cell growth by binding to calcineurin b homologous protein 1.
Kim BS; Lee K; Jung HJ; Bhattarai D; Kwon HJ
Biochem Biophys Res Commun; 2015 Feb; 458(1):14-20. PubMed ID: 25603055
[TBL] [Abstract][Full Text] [Related]
46. Dynamic, site-specific interaction of hypoxia-inducible factor-1alpha with the von Hippel-Lindau tumor suppressor protein.
Yu F; White SB; Zhao Q; Lee FS
Cancer Res; 2001 May; 61(10):4136-42. PubMed ID: 11358837
[TBL] [Abstract][Full Text] [Related]
47. Nanobody medicated immunoassay for ultrasensitive detection of cancer biomarker alpha-fetoprotein.
Chen J; He QH; Xu Y; Fu JH; Li YP; Tu Z; Wang D; Shu M; Qiu YL; Yang HW; Liu YY
Talanta; 2016 Jan; 147():523-30. PubMed ID: 26592642
[TBL] [Abstract][Full Text] [Related]
48. Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors.
Chau NM; Rogers P; Aherne W; Carroll V; Collins I; McDonald E; Workman P; Ashcroft M
Cancer Res; 2005 Jun; 65(11):4918-28. PubMed ID: 15930314
[TBL] [Abstract][Full Text] [Related]
49. Fentanyl activates hypoxia-inducible factor 1 in neuronal SH-SY5Y cells and mice under non-hypoxic conditions in a μ-opioid receptor-dependent manner.
Daijo H; Kai S; Tanaka T; Wakamatsu T; Kishimoto S; Suzuki K; Harada H; Takabuchi S; Adachi T; Fukuda K; Hirota K
Eur J Pharmacol; 2011 Sep; 667(1-3):144-52. PubMed ID: 21703258
[TBL] [Abstract][Full Text] [Related]
50. Effects of geldanamycin on HIF-1alpha mediated angiogenesis and invasion in prostate cancer cells.
Alqawi O; Moghaddas M; Singh G
Prostate Cancer Prostatic Dis; 2006; 9(2):126-35. PubMed ID: 16432534
[TBL] [Abstract][Full Text] [Related]
51. Differential roles of Sirt1 in HIF-1α and HIF-2α mediated hypoxic responses.
Yoon H; Shin SH; Shin DH; Chun YS; Park JW
Biochem Biophys Res Commun; 2014 Jan; 444(1):36-43. PubMed ID: 24423936
[TBL] [Abstract][Full Text] [Related]
52. Hypoxia inducible factor-1 alpha expression in human normal and osteoarthritic chondrocytes.
Coimbra IB; Jimenez SA; Hawkins DF; Piera-Velazquez S; Stokes DG
Osteoarthritis Cartilage; 2004 Apr; 12(4):336-45. PubMed ID: 15023385
[TBL] [Abstract][Full Text] [Related]
53. Hypoxia-inducible factor 1alpha cDNA cloning and its mRNA and protein tissue specific expression in domestic yak (Bos grunniens) from Qinghai-Tibetan plateau.
Wang DP; Li HG; Li YJ; Guo SC; Yang J; Qi DL; Jin C; Zhao XQ
Biochem Biophys Res Commun; 2006 Sep; 348(1):310-9. PubMed ID: 16876112
[TBL] [Abstract][Full Text] [Related]
54. Mechanism of TNF-α autocrine effects in hypoxic cardiomyocytes: initiated by hypoxia inducible factor 1α, presented by exosomes.
Yu X; Deng L; Wang D; Li N; Chen X; Cheng X; Yuan J; Gao X; Liao M; Wang M; Liao Y
J Mol Cell Cardiol; 2012 Dec; 53(6):848-57. PubMed ID: 23085511
[TBL] [Abstract][Full Text] [Related]
55. [Effect of silencing HIF-1alpha by RNA interference on expression of vascular endothelial growth factor in osteosarcoma cell line SaOS-2 under hypoxia].
Wu Q; Yang SH; Wang RY; Ye SN; Xia T; Ma DZ
Ai Zheng; 2005 May; 24(5):531-5. PubMed ID: 15890092
[TBL] [Abstract][Full Text] [Related]
56. Selection and Characterization of Specific Nanobody Against Human Immunoglobulin G.
Kazemi-Lomedasht F; Behdani M; Rahimpour A; Habibi-Anbouhi M; Poshang-Bagheri K; Shahbazzadeh D
Monoclon Antib Immunodiagn Immunother; 2015 Jun; 34(3):201-5. PubMed ID: 26090598
[TBL] [Abstract][Full Text] [Related]
57. VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer
Kang G; Hu M; Ren H; Wang J; Cheng X; Li R; Yuan B; Balan Y; Bai Z; Huang H
Cancer Biol Med; 2021 Apr; 18(3):772-87. PubMed ID: 33830713
[TBL] [Abstract][Full Text] [Related]
58. NaLi-H1: A universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies.
Moutel S; Bery N; Bernard V; Keller L; Lemesre E; de Marco A; Ligat L; Rain JC; Favre G; Olichon A; Perez F
Elife; 2016 Jul; 5():. PubMed ID: 27434673
[TBL] [Abstract][Full Text] [Related]
59. Engineering an anti-granulocyte colony stimulating factor receptor nanobody for improved affinity.
Bakherad H; Farahmand M; Setayesh N; Ebrahim-Habibi A
Life Sci; 2020 Sep; 257():118052. PubMed ID: 32634431
[TBL] [Abstract][Full Text] [Related]
60. Development, Screening, and Validation of Camelid-Derived Nanobodies for Neuroscience Research.
Gavira-O'Neill CE; Dong JX; Trimmer JS
Curr Protoc Neurosci; 2020 Dec; 94(1):e107. PubMed ID: 33185319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
